Recombinant protein corresponding to human VEGF165 expressed in E. coli.
The vascular endothelial growth factor (VEGF) family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF. VEGF and its receptor system have been shown to be the fundamental regulators in the cell signaling of angiogenesis. Most tumors have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine linked to this process. To date 5 different isoforms of VEGF have been described. These isoforms are generated as the result of alternative splicing from a single VEGF gene. These various isoforms have been shown to bind to two tyrosine-kinase receptors flt-1 (VEGFR-1) and flk-1/KDR (VEGFR-2), which have been found to be expressed almost exclusively on endothelial cells. Applications: Suitable for use in Neutralization, ELISA, Immunohistochemistry and Western Blot. Other applications not tested. Recommended Dilution: Immunohistochemistry (Formalin-fixed paraffin embedded): 5-15ug/ml with a 30 minute incubation at RT or an overnight incubation at 4C. Requires HIER using sodium citrate buffer pH6.0 prior to staining. Neutralization: 0.05-0.1ug/ml yields one-half maximal inhibition [ND50] of the biological activity (10ng/ml). ELISA (Sandwich): 0.5-2ug/ml (100ul/well). Used in conjunction with V2110-09B Vascular Endothelial Growth Factor (VEGF) (Biotin) allows detection of 0.2-0.4ng/well of recombinant hVEGF. Western Blot: 0.1-0.2ug/ml. Used in conjunction with compatible secondary reagents the detection limit is 1.5-3.0ng/lane, under either reducing or non-reducing conditions. Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized and reconstituted products are stable for 12 months after receipt at -20C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer
